Liver transplantation has emerged as the final therapeutic modality for patients with end-stage liver diseases due to HBV. Although liver transplantation is not performed in many countries due to technical and financial limitations, this life saving therapeutic approach would be increased globally from now. HBV should be properly managed in patients waiting for liver transplantation. Also, HBV infection should be considered seriously in donor because HBV past HBV infection may be detected in as high as 70% normal subjects in some hyperendemic countries. Management of HBV is also a challenging job in liver transplanted subjects. HBV can flare up in these patients due to use of immune suppressive drugs. Comprehensive idea about HBV in recipient and donor in the context of liver transplantation is necessary for saving life of patients in late stage liver failure.